• 1. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 2. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 3. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 4. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 5. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Glycosyl compounds

Research Briefing on 8-Hydroxyquinoline-β-D-glucopyranoside (CAS: 29266-96-4): Recent Advances and Applications

8-Hydroxyquinoline-β-D-glucopyranoside (CAS: 29266-96-4) is a glycosylated derivative of 8-hydroxyquinoline, a compound known for its versatile biological activities, including antimicrobial, anticancer, and metal-chelating properties. Recent studies have explored the potential of this glucopyranoside derivative in various therapeutic and diagnostic applications, leveraging its enhanced solubility and bioavailability compared to its parent compound. This briefing synthesizes the latest research findings on 8-Hydroxyquinoline-β-D-glucopyranoside, focusing on its synthesis, mechanisms of action, and emerging applications in the chemical, biological, and pharmaceutical fields.

Recent advancements in synthetic chemistry have enabled the efficient production of 8-Hydroxyquinoline-β-D-glucopyranoside through enzymatic glycosylation and chemical conjugation methods. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a high-yield enzymatic synthesis route using β-glucosidase, achieving over 85% conversion efficiency. This method not only improves scalability but also reduces the environmental impact compared to traditional chemical synthesis. The study highlighted the compound's stability under physiological conditions, making it a promising candidate for drug development.

In the realm of antimicrobial research, 8-Hydroxyquinoline-β-D-glucopyranoside has shown significant activity against multidrug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. A 2024 study in Antimicrobial Agents and Chemotherapy reported that the glucopyranoside derivative exhibited a 4-fold lower minimum inhibitory concentration (MIC) compared to 8-hydroxyquinoline alone, attributed to its improved cellular uptake. The study also identified its synergistic effects with conventional antibiotics, suggesting potential for combination therapies.

Oncology research has also explored the anticancer properties of 8-Hydroxyquinoline-β-D-glucopyranoside, particularly its role as a metal-chelating agent. A recent investigation in Bioorganic & Medicinal Chemistry Letters (2024) revealed its ability to selectively bind iron and copper ions in tumor microenvironments, inducing oxidative stress and apoptosis in cancer cells. In vitro studies using breast cancer cell lines (MCF-7 and MDA-MB-231) demonstrated dose-dependent cytotoxicity, with IC50 values ranging from 12-18 μM. Notably, the compound showed minimal toxicity to normal human fibroblasts at therapeutic concentrations, highlighting its potential selectivity.

Beyond therapeutic applications, 8-Hydroxyquinoline-β-D-glucopyranoside has emerged as a valuable tool in diagnostic imaging. Researchers have developed fluorescent probes based on this compound for detecting metal ions in biological systems. A 2023 study in Analytical Chemistry described a novel zinc(II)-selective probe with a 20-fold fluorescence enhancement upon binding, enabling real-time monitoring of zinc dynamics in live cells. This application could provide insights into neurodegenerative diseases where metal ion dyshomeostasis plays a critical role.

Despite these promising developments, challenges remain in the clinical translation of 8-Hydroxyquinoline-β-D-glucopyranoside. Pharmacokinetic studies in animal models have shown rapid renal clearance, necessitating formulation optimization for sustained delivery. Current research efforts focus on nanoparticle encapsulation and prodrug strategies to address this limitation. Additionally, comprehensive toxicological assessments are underway to evaluate long-term safety profiles.

In conclusion, 8-Hydroxyquinoline-β-D-glucopyranoside represents a multifaceted compound with growing importance in chemical biology and pharmaceutical research. Its unique properties bridge therapeutic and diagnostic applications, offering opportunities for innovative drug design and biomedical tools. Future research directions may explore its potential in neurodegenerative diseases, given its metal-chelating and neuroprotective capabilities, as well as its role in combating antimicrobial resistance. Continued interdisciplinary collaboration will be essential to fully realize the clinical potential of this versatile molecule.

• 126787-65-3(Indoxyl β-D-Galactopyranoside)
• 195386-02-8(.beta.-D-Ribofuranoside, 5-quinolinyl)
• 36473-36-6(5-Iodo-3-indolyl-β-D-galactopyranoside)
• 113079-84-8(8-Hydroxyquinoline-b-D-galactopyranoside)
• 97753-82-7(5-Bromo-3-indolyl β-D-galactopyranoside)
• 487-60-5(Indican)
• 207728-71-0(b-D-Glucopyranosiduronic acid,8-quinolinyl, monosodium salt (9CI))
• 16934-09-1(5-Bromo-3-indolyl b-D-glucopyranoside)
• 14683-61-5(8-Hydroxyquinoline-b-D-glucuronide)
• 124613-91-8(b-D-Glucopyranoside,5-bromo-1H-indol-3-yl 4-O-b-D-glucopyranosyl-)